. The genotype of the Nf1 mutant mice was incorrectly described. The correct text for Methods appears below. Mice and treatment procedures. Mx1-Cre;Nf1tm1Par/tm1Tyj (referred to as Mx1-Cre;Nf1flox/-) and control mice (Nf1flox/+) were generated and treated with pIpC (SigmaAldrich) at 3-5 days, as described previously (16). In addition, corrected sentences describing the Nf1 mutant mice in the Introduction and Results and Discussion appear below. To address this question, we administered 901 to Mx1-Cre;Nf1flox/-mice with MPN. We first assessed the pharmacodynamic properties of 901 in WT and Mx1-Cre;Nf1flox/-(Nf1 mutant) mice that received an oral gavage dose of 5 mg/kg/d for 5 days. We randomly assigned Mx1-Cre;Nf1flox/-mice (n = 35) and their WT littermates (n = 38) to treatment with 901 (at a daily dose of 5 mg/kg) or control vehicle for 10 weeks or until the mice became moribund. Progressive anemia with elevated reticulocyte counts and massive splenomegaly suggested that Mx1-Cre;Nf1flox/-mice with MPN have ineffective erythropoiesis. In striking contrast, profiling revealed a largely inverted ratio of early-to-late erythroblasts in Mx1-Cre;Nf1flox/-mice, with 10-fold expansion in the percentage of cells in region II, and a reciprocal decline in the number of erythroblasts progressing to region IV ( Figure 2C ). To further characterize the hematopoietic compartment […] Corrigendum Find the latest version:
) and control mice (Nf1 flox/+ ) were generated and treated with pIpC (Sigma-Aldrich) at 3-5 days, as described previously (16).
In addition, corrected sentences describing the Nf1 mutant mice in the Introduction and Results and Discussion appear below.
To address this question, we administered 901 to Mx1-Cre;Nf1 flox/-mice with MPN.
We first assessed the pharmacodynamic properties of 901 in WT and Mx1-Cre;Nf1 flox/-(Nf1 mutant) mice that received an oral gavage dose of 5 mg/kg/d for 5 days.
We randomly assigned Mx1-Cre;Nf1 flox/-mice (n = 35) and their WT littermates (n = 38) to treatment with 901 (at a daily dose of 5 mg/kg) or control vehicle for 10 weeks or until the mice became moribund.
Progressive anemia with elevated reticulocyte counts and massive splenomegaly suggested that Mx1-Cre;Nf1 flox/-mice with MPN have ineffective erythropoiesis.
In striking contrast, profiling revealed a largely inverted ratio of early-to-late erythroblasts in Mx1-Cre;Nf1 flox/-mice, with 10-fold expansion in the percentage of cells in region II, and a reciprocal decline in the number of erythroblasts progressing to region IV ( Figure 2C In addition, corrected sentences describing the Nf1 mutant mice in the figure legends appear below.
[ Figure 1 ] 901 reduces myeloproliferation and enhances erythropoiesis in Mx1-Cre;Nf1 flox/-(Nf1) mice.
[ Figure 2 ] Hematopoietic tissues from 6-month-old Mx1-Cre;Nf1 flox/-(Nf1) and WT mice treated with 901 or vehicle were analyzed at the end of the trial.
[ Figure 3 ] 901 normalizes early myelo-erythroid populations in Mx1-Cre;Nf1 flox/-(Nf1) mice.
Finally, the online version of the supplemental data has been updated to indicate the correct genotype of Nf1 mutant mice in Supplemental Figures 2-5.
The authors regret the errors.
